Reading in the Daily telegraph from London yesterday: A financial adviser, Mr Haefele from UBS believes that the focus for investors should be in emerging markets health care and above all oncology and immunotherapy, a sector which apparently has 300 clinical trials running with treatments cost in excess of $100,000 per patient. He points out … Continue reading 60% increase in the cost of treating cancer patients